Lisinopril/Hydrochlorothiazide: Difference between revisions
Ahmed Zaghw (talk | contribs) Created page with "{{DrugProjectFormSinglePage |authorTag={{AZ}}, {{AM}} |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content) |fdaLIADAdult=<h4>Conditi..." |
Ahmed Zaghw (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
{{DrugProjectFormSinglePage | {{DrugProjectFormSinglePage | ||
|authorTag={{AZ}}, {{AM}} | |authorTag={{AZ}}, {{AM}} | ||
|genericName=Prinzide; Zestoretic | |||
|aOrAn=an | |||
|drugClass=Angiontensin converting enzyme inhibitor, Thiazide diuretic | |||
|hasBlackBoxWarning=Yes | |||
|adverseReactions=[[hypotension]] (1.2% to 10.8% ), [[syncope]] (5.1% to 7% ), [[hyperkalemia]] (2.2% to 6.4% ), [[dizziness]] (5.4% to 18.9% ), [[headache]] (4.4% to 5.7% ), renal function tests abnormal and [[cough]] (3.5% ) | |||
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content) | |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content) | ||
|fdaLIADAdult=<h4>Condition 1</h4> | |fdaLIADAdult=<h4>Condition 1</h4> |
Revision as of 13:40, 9 April 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2], Amr Marawan, M.D. [3]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
{{{blackBoxWarningTitle}}}
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)
|
Overview
Lisinopril/Hydrochlorothiazide is an Angiontensin converting enzyme inhibitor, Thiazide diuretic that is FDA approved for the {{{indicationType}}} of {{{indication}}}. There is a Black Box Warning for this drug as shown here. Common adverse reactions include hypotension (1.2% to 10.8% ), syncope (5.1% to 7% ), hyperkalemia (2.2% to 6.4% ), dizziness (5.4% to 18.9% ), headache (4.4% to 5.7% ), renal function tests abnormal and cough (3.5% ).
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
<h4>Condition 1</h4>
- Dosing Information
- (Dosage)
Off-Label Use and Dosage (Adult)
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Lisinopril/Hydrochlorothiazide FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Contraindications
There is limited information regarding Lisinopril/Hydrochlorothiazide Contraindications in the drug label.
Warnings
{{{blackBoxWarningTitle}}}
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)
|
There is limited information regarding Lisinopril/Hydrochlorothiazide Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Lisinopril/Hydrochlorothiazide Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Lisinopril/Hydrochlorothiazide Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Lisinopril/Hydrochlorothiazide Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Lisinopril/Hydrochlorothiazide in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Lisinopril/Hydrochlorothiazide in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Lisinopril/Hydrochlorothiazide during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Lisinopril/Hydrochlorothiazide in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Lisinopril/Hydrochlorothiazide in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Lisinopril/Hydrochlorothiazide in geriatric settings.
Gender
There is no FDA guidance on the use of Lisinopril/Hydrochlorothiazide with respect to specific gender populations.
Race
There is no FDA guidance on the use of Lisinopril/Hydrochlorothiazide with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Lisinopril/Hydrochlorothiazide in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Lisinopril/Hydrochlorothiazide in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Lisinopril/Hydrochlorothiazide in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Lisinopril/Hydrochlorothiazide in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Lisinopril/Hydrochlorothiazide Administration in the drug label.
Monitoring
There is limited information regarding Lisinopril/Hydrochlorothiazide Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Lisinopril/Hydrochlorothiazide and IV administrations.
Overdosage
There is limited information regarding Lisinopril/Hydrochlorothiazide overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Lisinopril/Hydrochlorothiazide Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Lisinopril/Hydrochlorothiazide Mechanism of Action in the drug label.
Structure
There is limited information regarding Lisinopril/Hydrochlorothiazide Structure in the drug label.
Pharmacodynamics
There is limited information regarding Lisinopril/Hydrochlorothiazide Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Lisinopril/Hydrochlorothiazide Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Lisinopril/Hydrochlorothiazide Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Lisinopril/Hydrochlorothiazide Clinical Studies in the drug label.
How Supplied
There is limited information regarding Lisinopril/Hydrochlorothiazide How Supplied in the drug label.
Storage
There is limited information regarding Lisinopril/Hydrochlorothiazide Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Lisinopril/Hydrochlorothiazide |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Lisinopril/Hydrochlorothiazide |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Lisinopril/Hydrochlorothiazide Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Lisinopril/Hydrochlorothiazide interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Lisinopril/Hydrochlorothiazide Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Lisinopril/Hydrochlorothiazide Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.